DISSECTING THE THERAPEUTIC ROLE OF CARBON MONOXIDE (CO) IN PROSTATE CANCER

GASTON PASCUAL; PABLO SANCHIS; ROCIO SENIUK; AGUSTINA SABATER; JAVIER COTIGNOLA; ELBA VAZQUEZ; ROBERTO MOTTERLINI; AYELEN TORO; GERALDINE GUERON

Congreso; LXVIII Reunión Anual de la Sociedad Argentina de Investigación Clínica; 2023

Several studies have placed carbon monoxide (CO) as an anti-inflammatory, anti-apoptotic, and anti-proliferative gasotransmitter. Over the past few years, CO releasing molecules (CO-RMs) have been developed to deliver controlled amounts of CO to cells and tissues. They are also being tested as potential therapeutic agents. We hypothesized that CO-RMs might modulate processes associated with prostate cancer (PCa) development. Therefore, in this work we aimed at identifying the impact of CO-RMs on PCa cells. First, we assessed the release of CO from three water-soluble CO-RMs (CORM-3, CORM-A1 and CORM-401) using a well-established myoglobin assay (spectrophotometric analysis of the conversion of deoxy-myoglobin to carbonmonoxy-myoglobin). Then, we treated PC3 cells (PCa cell line) with the 3 CO-RMs (25-200 µM, 6 h): 1) CORM-3 (ruthenium-based); 2) CORM-A1 (boronocarbonate-based); and 3) CORM-401 (manganese-based); and assessed cell viability (MTS assay), cell adhesion (cristal violet staining), cell migration (wound healing assay), oxidative stress (DCFH staining followed by confocal microscopy) and cell metabolism (ATP production assay). We did not observe changes in cell viability for the range of concentrations tested. However, we found a significant increase in the number of adherent cells (p